<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36818469</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms.</ArticleTitle><Pagination><StartPage>1033651</StartPage><MedlinePgn>1033651</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1033651</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1033651</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Long COVID is the overarching name for a wide variety of disorders that may follow the diagnosis of acute SARS-COVID-19 infection and persist for weeks to many months. Nearly every organ system may be affected.</AbstractText><AbstractText Label="METHODS">We report nine patients suffering with Long COVID for 101 to 547 days. All exhibited significant perturbations of their immune systems, but only one was known to be immunodeficient prior to the studies directed at evaluating them for possible treatment. Neurological and cardiac symptoms were most common. Based on this data and other evidence suggesting autoimmune reactivity, we planned to treat them for 3 months with long-term high-dose immunoglobulin therapy. If there was evidence of benefit at 3 months, the regimen was continued.</AbstractText><AbstractText Label="RESULTS">The patients' ages ranged from 34 to 79 years-with five male and four female patients, respectively. All nine patients exhibited significant immune perturbations prior to treatment. One patient declined this treatment, and insurance support was not approved for two others. The other six have been treated, and all have had a significant to remarkable clinical benefit.</AbstractText><AbstractText Label="CONCLUSION">Long-term high-dose immunoglobulin therapy is an effective therapeutic option for treating patients with Long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Thompson, Thornton, Ainger and Garvy.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>John S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thornton</LastName><ForeName>Alice C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ainger</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kentucky, College of Medicine, Lexington, KY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garvy</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Molecular Genetics, College of Medicine, University of Kentucky, Lexington, KY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">immune perturbation</Keyword><Keyword MajorTopicYN="N">microvasculitis</Keyword><Keyword MajorTopicYN="N">neuropathy</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36818469</ArticleId><ArticleId IdType="pmc">PMC9932260</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1033651</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Patterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. . The emerging spectrum of COVID-19 neurology: Clinical, radiological, and clinical findings. Brain (2020) 143:3104&#x2013;20. doi:&#xa0;10.1093/brain/awaa240</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M, Maralakun M, Garg S, Dhooria S, Sehgai I, Bhalla AS, et al. . The conundrum of &#x201c;Long covid-COVID-19&#x201d;: A narrative review. Int J Gen Med (2021) 14:2491&#x2013;506. doi: 10.2147/IJGM.S316708</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S316708</ArticleId><ArticleId IdType="pmc">PMC8214209</ArticleId><ArticleId IdType="pubmed">34163217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. . More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep (2021) 11:16144. doi:&#xa0;10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and pyschiatric outcomes in 236,379 survivors of covid-19: A retrospective cohort using electronic health records. Lancet Psychiatry (2021) 8:416&#x2013;7. doi:&#xa0;10.1016/S2215-0366(21)00094-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00094-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Payus AO, Jeffree MS, Ohn MH, Tan HJ, Ibraham A, Chia YK, et al. . Immune-mediated neurological syndrome in SARS-CoV-2 infection: A review of the literature on autoimmune encephalitis. Covid-19 Neurol Sci (2022) 43:1533&#x2013;47. doi: 10.1007/s10072-021-05785-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05785-z</ArticleId><ArticleId IdType="pmc">PMC8635316</ArticleId><ArticleId IdType="pubmed">34853897</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilazi M, Duffy EY, Thakkar A, Michos ED. COVID and cardiovascular disease: What we know in 2021. Curr Atheroscler Rep (2021) 23:37. doi:&#xa0;10.1007/s11883-021-00935-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11883-021-00935-2</ArticleId><ArticleId IdType="pmc">PMC8117457</ArticleId><ArticleId IdType="pubmed">33983522</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakawa JM, Kuno T, Mikami T, Takagi H, Gronseth G. Clinical characteristics of stroke with COVID-19: A systematic review and meta-analysis. J Stroke Cerebrovascular Dis (2020) 29:105288. doi:&#xa0;10.1016/jstrokecerebrovasdis.2020.105288</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/jstrokecerebrovasdis.2020.105288</ArticleId><ArticleId IdType="pmc">PMC7456266</ArticleId><ArticleId IdType="pubmed">32992199</ArticleId></ArticleIdList></Reference><Reference><Citation>Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POS) and other autonomic disorders after covid-19 infection: A case series of 20 patients. Immunol Res (2021) 69:m205&#x2013;211. doi:&#xa0;10.1007/s12026-021-09185-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-021-09185-5</ArticleId><ArticleId IdType="pmc">PMC8009458</ArticleId><ArticleId IdType="pubmed">33786700</ArticleId></ArticleIdList></Reference><Reference><Citation>Oaklander AL, Mills AJ, Kelley M, Toran LS, Smith B, Dalakas M, et al. . Peripheral neuropathy evaluations of patients with prolonged long COVID. Neurol Neuroimmunol Neuroinflamm. (2022) 9:e1146. doi:&#xa0;10.1212/NXI.000000000001146</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.000000000001146</ArticleId><ArticleId IdType="pmc">PMC8889896</ArticleId><ArticleId IdType="pubmed">35232750</ArticleId></ArticleIdList></Reference><Reference><Citation>Salle V. Coronavirus-induced autoimmunity. Review. Clin Immunol (2021) 226:108694. doi:&#xa0;10.1016/j.clim.2021.108694</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108694</ArticleId><ArticleId IdType="pmc">PMC8005338</ArticleId><ArticleId IdType="pubmed">33610741</ArticleId></ArticleIdList></Reference><Reference><Citation>Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res (2020) 69:379&#x2013;88. doi: 10.33549/physiolres.934492</Citation><ArticleIdList><ArticleId IdType="doi">10.33549/physiolres.934492</ArticleId><ArticleId IdType="pmc">PMC8648321</ArticleId><ArticleId IdType="pubmed">32469225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. . Autonomic dysfunction in &#x2018;long COVID&#x2019;: Rationale, physiology and management strategies. Clin Med (Lond). (2021) 21:e63&#x2013;7. doi:&#xa0;10.7861/clinmed.2020-0896</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0896</ArticleId><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, David P, Arnheim D, Shoenfeld Y. The autonomic aspects of the post-COVID19 syndrome. Autoimmune Res (2022) 21:11&#x2013;13. doi:&#xa0;10.1016/j.autrev.2022.103071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103071</ArticleId><ArticleId IdType="pmc">PMC8848724</ArticleId><ArticleId IdType="pubmed">35182777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez CV, Theel E, Binnicker M, Toledano M, Mckeon A. Autoimmune encephalitis after SARS-Co-2 infection. Neurology (2021) 97(23). doi:&#xa0;10.1212/WNL.0000000012931</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000012931</ArticleId><ArticleId IdType="pmc">PMC8671045</ArticleId><ArticleId IdType="pubmed">34635560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousuf F, King R, Ainger T, Hessler A. Autoimmune encephalitis following recovery of severe acute respiratory syndrome coronavirus 2(SARS-C0-2) infection (2756). Neurology (2021) 96(15-suppplement).</Citation></Reference><Reference><Citation>Pruss H. Post viral autoimmune encephalitis: Manifestations in children and adults. Curr Op Opin.Neurol (2017) 30:327&#x2013;33. doi:&#xa0;10.1097/WCO.0000000000000445</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000445</ArticleId><ArticleId IdType="pubmed">28234798</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlpine LS, Lifland B, Check JR, Angarita JR, Gustavo A, Ngo TT, et al. . Remission of subacute psychosis in a covid-19 patient with an antineuronal autoantibody after treatment with intravenous immunoglobulin. Biol Psychiatry (2021) 90:e23&#x2013;e26.0815. doi: 10.1016/j.biopsych.2021.03.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2021.03.033</ArticleId><ArticleId IdType="pmc">PMC8041149</ArticleId><ArticleId IdType="pubmed">34001372</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Z, Feng Y, Zhong L, Xied Q, Lei M, Liu Z, et al. . Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: A multicenter retrospective cohort study. Clin Trans Immunol (2020). doi:&#xa0;10.1002/cti2.1192</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1192</ArticleId><ArticleId IdType="pmc">PMC7557105</ArticleId><ArticleId IdType="pubmed">33082954</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. . Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect (2020) 81:318&#x2013;56. doi:&#xa0;10.1016/j.jinf.2020.03.04</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.04</ArticleId><ArticleId IdType="pmc">PMC7151471</ArticleId><ArticleId IdType="pubmed">32283154</ArticleId></ArticleIdList></Reference><Reference><Citation>Danieli M, Piga MA, Paladini A, Longhi E, Mezzanotte C, Moroncini G, et al. . Intravenous immunoglobulin as an important adjunct in the prevention and therapy of corona virus 2019 disease. Scandavian J Immunol (2021) 94:e13101. doi:&#xa0;10.1111/sji.13101</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.13101</ArticleId><ArticleId IdType="pmc">PMC8646640</ArticleId><ArticleId IdType="pubmed">34940980</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynaga E, Carrillo J, Santos JR, Roure S, Mateu L, Paredes R, et al. . Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series. Clin Microbiol Infect (2021) 27:651&#x2013;2. doi:&#xa0;10.1016/j.cmi.2020.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.10.010</ArticleId><ArticleId IdType="pmc">PMC7550893</ArticleId><ArticleId IdType="pubmed">33065237</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang H-r, Cheng X, Li Y, Luo W-w, Zhang Q-z, Peng W-w. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease (Covid-19): A meta-analysis. Int Immunopharmacol (2021) 96:107732. doi:&#xa0;10.1016/j.intimp2021.107732</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp2021.107732</ArticleId><ArticleId IdType="pmc">PMC8084608</ArticleId><ArticleId IdType="pubmed">34162133</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi M, Mehni MB, Akbarian M, Ghazi SF, Rad NK, Moradi O, et al. . The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients: A retrospective, multi-centric cohort study. Exp Ther Med (2021) 27:18. doi:&#xa0;10.1186/s4001-022-00636-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s4001-022-00636-8</ArticleId><ArticleId IdType="pmc">PMC8811009</ArticleId><ArticleId IdType="pubmed">35115056</ArticleId></ArticleIdList></Reference><Reference><Citation>Moradimajd P, Samaee H, Sedigh-Maroufi S, Kourosh-Aami M, Mohsenzadagan M. Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence. J Med Virol (2021) 93:2675&#x2013;82. doi:&#xa0;10.1002/jmv.26727</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26727</ArticleId><ArticleId IdType="pubmed">33314173</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu R, Cheng T, Yin Z, Liu D, Xu L, Li Y, et al. . Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. Emerg Microbes Infect (2018) 7:1&#x2013;15. doi:&#xa0;10.1038/s41426-017-0003-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-017-0003-z</ArticleId><ArticleId IdType="pmc">PMC5837151</ArticleId><ArticleId IdType="pubmed">29323107</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu x, Cao w, Li T. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. Front Immunol (2020) 11:1660. doi:&#xa0;10.3389/fimmu.2020.01660</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01660</ArticleId><ArticleId IdType="pmc">PMC7372093</ArticleId><ArticleId IdType="pubmed">32760407</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Bitzogli B, Alexopoulos H. Anti-SARS-CoV-2 antibodies within IVIg preparations: Cross-reactivities with seasonal coronaviruses, natural autoimmunity, and therapeutic implications. Front Immunol (2021) 12:627285. doi: 10.3389/fimmu.2021.627285</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.627285</ArticleId><ArticleId IdType="pmc">PMC7925824</ArticleId><ArticleId IdType="pubmed">33679770</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk A, Covini-Souris C, Keuhnel D, De Mey C, Romisch J, Schmit T. SARS-CoV-2 neutralization in convalescent plasma and commercial lots of plasma-derived immunoglobulin. BioDrugs (2022) 36:41&#x2013;53. doi:&#xa0;10.1007/s40259-00511-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-00511-9</ArticleId><ArticleId IdType="pmc">PMC8628143</ArticleId><ArticleId IdType="pubmed">34843105</ArticleId></ArticleIdList></Reference><Reference><Citation>Farcet MR, Karbiener M, Schwaiger J, LLk R, Kreil TR. Rapidly increasing severe acute 26 (respiratory syndrome coronavirus 2 neutralization by intravenous immunoglobulin produced from plasma collected during the 2020 pandemic. J Infect Dis (2022) 226:1357&#x2013;61. doi: 10.1093/infdis/jiab142</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab142</ArticleId><ArticleId IdType="pmc">PMC7989343</ArticleId><ArticleId IdType="pubmed">33725725</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan SC, Berg A, Shin B, Vo A, Ammerman N, Zhang R. Intravenous immunoglobulin contains IgG neutralizing antibodies to SARS-CoV-2. Am J Transplant (2022) 22:2484&#x2013;5. doi: 10.1111/ajt.17086</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.17086</ArticleId><ArticleId IdType="pmc">PMC9348077</ArticleId><ArticleId IdType="pubmed">35514147</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunneman JD, Quast. I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neuroltherapeutics (2016) 13:34&#x2013;46. doi: 10.1007/s13311-015-0391-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0391-5</ArticleId><ArticleId IdType="pmc">PMC4720677</ArticleId><ArticleId IdType="pubmed">26400261</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC. Update on intravenous immunoglobulin in neurology: Modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. Neurotherapeutics (2021) 18:2397&#x2013;418. doi:&#xa0;10.1007/s13311-021-01108</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-021-01108</ArticleId><ArticleId IdType="pmc">PMC8585501</ArticleId><ArticleId IdType="pubmed">34766257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoste L, van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to covid-19: a systematic review. Eur J Pediatr (2021) 180:2019&#x2013;34.&gt; doi: 10.1007/s00431-021-03993-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-03993-5</ArticleId><ArticleId IdType="pmc">PMC7890544</ArticleId><ArticleId IdType="pubmed">33599835</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoian A, Baiko Z, Maier S, Coiflinc RA, Grigorescu BL, Motataianu A, et al. . High-dose intravenous immunoglobulin as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review). Exp Ther Med (2021) 22:1182. doi: 10.3892/etm.2021.10616</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10616</ArticleId><ArticleId IdType="pmc">PMC8406741</ArticleId><ArticleId IdType="pubmed">34475972</ArticleId></ArticleIdList></Reference><Reference><Citation>Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. . Autoimmune encephalitis: Proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry (2021) 92:757&#x2013;68. doi:&#xa0;10.1136/innp-2020-325300</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/innp-2020-325300</ArticleId><ArticleId IdType="pmc">PMC8223680</ArticleId><ArticleId IdType="pubmed">33649022</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeannaret V, Winkel D, Risman A, Shi H, Gombolay G. Post-infectious rhombencephalitis after coronavirus-19 infection: A case report and literature review. J Neuroimunol (2021) 357:577623. doi:&#xa0;10.1016/j.neurim.2021.55623</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurim.2021.55623</ArticleId><ArticleId IdType="pmc">PMC8164357</ArticleId><ArticleId IdType="pubmed">34082192</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Chandra A, Ray BK, Pandi A. Treatment related fluctuation and response to intravenous immunoglobulin therapy in post covid-19 Guillain-barre syndrome. Diabetes Metab Syndr (2021) 15:102246. doi: 10.1016/j.dsx.2021.102246</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102246</ArticleId><ArticleId IdType="pmc">PMC8361026</ArticleId><ArticleId IdType="pubmed">34416468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavrilova N, Kamaevas E, Ignatova M, Ryabkova V, Lukashernko M, Soprun L, et al. . Intravenous immunoglobulin in dysautonomia. Review. Clin Immunol (2022) 240:109039. doi:&#xa0;10.1016/j</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j</ArticleId><ArticleId IdType="pubmed">35569781</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriquez B, Hoepner R, Salmen A, Kamber N, JZ&#x2019;Graggen W. Immunomodulatory treatment in postural tachycardia syndrome: A case series. Eur J Neurol (2021) 28:m1692&#x2013;1697. doi: 10.1111/ene.14711</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14711</ArticleId><ArticleId IdType="pubmed">33382525</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker WH, Moudgil R, Wilson RG, Tonelli AR, Mavuga KAS, Sing TK. COVID-19 and postural tachycardia syndrome: A case series. Eur Heart J Case Rep (2021) 5:mytab325. doi:&#xa0;10.1093/ehjcr/ytab325</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytab325</ArticleId><ArticleId IdType="pmc">PMC8716749</ArticleId><ArticleId IdType="pubmed">34993394</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalvo M, Nallapaneni P, Hassan. S, Nurko S, Pittock SJ, Klievener J. Autoimmune gastrointestinal dysmotility following SARS-Co-2 infection successfully treated with intravenous immunoglobulin. Neurogastroenterol Motil (2022) 34:e14314. doi:&#xa0;10.1111/nmo.14314</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14314</ArticleId><ArticleId IdType="pmc">PMC9257846</ArticleId><ArticleId IdType="pubmed">34984765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan F, Hope CM, Masavuli MG, Lynn MA, Mekonnen Z, Yeow AEL, et al. . Long-term perturbation of the peripheral immune system months after SARS-C0V-2 infection. BMC Med (2022) 20:26. doi:&#xa0;10.1186/s12916-021-02228-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol Int (2020) 44:1792&#x2013;7. doi:&#xa0;10.1002/cbin.11403</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.11403</ArticleId><ArticleId IdType="pmc">PMC7283672</ArticleId><ArticleId IdType="pubmed">32458561</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain-Syed F, Vad&#xe1;sz I, Wilhelm J, Walmrath HD, Seeger W, Birk HW, et al. . Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19. Am J Physiol Lung Cell Mol Physiol (2021) 320:L590&#x2013;9. doi:&#xa0;10.1152/ajplung.00359.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00359.2020</ArticleId><ArticleId IdType="pmc">PMC8057306</ArticleId><ArticleId IdType="pubmed">33237794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zubuchen Y, Taeschler P, Ballooz T, Menges D, Hasler S, et al. . Immunoglobulin signature predicts risk of post acute COVID-19 syndrome. Nat Publications (2022) 13:446. doi: 10.1038/s41467-021-27797-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Kimberly RP. Targeting the fc receptor in autoimmune disease. Expert Opin Ther Targets (2014) 18:335&#x2013;50. doi: 10.1517/14728222.2014.877891</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.2014.877891</ArticleId><ArticleId IdType="pmc">PMC4019044</ArticleId><ArticleId IdType="pubmed">24521454</ArticleId></ArticleIdList></Reference><Reference><Citation>Mkaddem SB, Benhamou M, Monteiro BC. Understanding fc receptor involvement in inflammatory diseases: From mechanisms to new therapeutic tools. Front Immunol (2019) 10:8. doi:&#xa0;10.3389/fimmu.2019.008</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.008</ArticleId><ArticleId IdType="pmc">PMC6481281</ArticleId><ArticleId IdType="pubmed">31057544</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation (1994) 57:553&#x2013;62. doi: 10.1097/00007890-199402270-00014</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007890-199402270-00014</ArticleId><ArticleId IdType="pubmed">8116041</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan SC, Peng A, Vo AA. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. Contrib Nephrol (2009) 162:13&#x2013;26. doi:&#xa0;10.1159/000170864</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000170864</ArticleId><ArticleId IdType="pubmed">19001810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferandez-Cruz E, Alecsandru D, Ramon SS. Mechanisms of action of immune globulin. Clin Exp Immunol (2009) 157(Suppl):1&#x2013;2. doi:&#xa0;10.1111/j.1365-2249.2009.03955/x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2009.03955/x</ArticleId><ArticleId IdType="pmc">PMC2715434</ArticleId><ArticleId IdType="pubmed">19630862</ArticleId></ArticleIdList></Reference><Reference><Citation>Reznik S. Intravenous immunoglobulin: A potential treatment for the post-acute sequelae of SARS-Cov-2 infection. BJBMS (2022) 22:660&#x2013;. doi:&#xa0;10.17305/bjbms.2021.6901</Citation><ArticleIdList><ArticleId IdType="doi">10.17305/bjbms.2021.6901</ArticleId><ArticleId IdType="pmc">PMC9392972</ArticleId><ArticleId IdType="pubmed">35150477</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Trials.gov . Immunotherapy for neurological post-acute sequelae of SARS-CoV-2. (2022) (National Institutes of Health: United States National Library of Medicine; ).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>